These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24390423)

  • 1. A multi-targeted approach to treating bone metastases.
    Camacho DF; Pienta KJ
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):545-53. PubMed ID: 24390423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
    Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone-targeting agents in prostate cancer.
    Suzman DL; Boikos SA; Carducci MA
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):619-28. PubMed ID: 24398856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
    Loberg RD; Logothetis CJ; Keller ET; Pienta KJ
    J Clin Oncol; 2005 Nov; 23(32):8232-41. PubMed ID: 16278478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions.
    Loberg RD; Gayed BA; Olson KB; Pienta KJ
    J Cell Biochem; 2005 Oct; 96(3):439-46. PubMed ID: 15988761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current trials using bone-targeting agents in prostate cancer.
    Tu SM; Lin SH
    Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examining the metastatic niche: targeting the microenvironment.
    Guise T
    Semin Oncol; 2010 Oct; 37 Suppl 2():S2-14. PubMed ID: 21111245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review).
    Ye L; Kynaston HG; Jiang WG
    Int J Mol Med; 2007 Jul; 20(1):103-11. PubMed ID: 17549396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases.
    Whang YM; Jung SP; Kim MK; Chang IH; Park SI
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases.
    Hiraga T
    Expert Opin Investig Drugs; 2016; 25(3):319-34. PubMed ID: 26778342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis.
    Bonfil RD; Chinni S; Fridman R; Kim HR; Cher ML
    Urol Oncol; 2007; 25(5):407-11. PubMed ID: 17826661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of osteoblastic bone metastases from prostate cancer.
    Ibrahim T; Flamini E; Mercatali L; Sacanna E; Serra P; Amadori D
    Cancer; 2010 Mar; 116(6):1406-18. PubMed ID: 20108337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging therapies in bone metastasis.
    Clément-Demange L; Clézardin P
    Curr Opin Pharmacol; 2015 Jun; 22():79-86. PubMed ID: 25935860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.
    Turner CJ; Edwards CM
    Curr Osteoporos Rep; 2016 Oct; 14(5):170-7. PubMed ID: 27566487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone metastases in the era of targeted treatments: insights from molecular biology.
    Dewulf J; Vangestel C; Verhoeven Y; van Dam P; Elvas F; Van den Wyngaert T; Clézardin P
    Q J Nucl Med Mol Imaging; 2019 Jun; 63(2):98-111. PubMed ID: 31298015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative bisphosphonate targets and mechanisms of action.
    Bukowski JF; Dascher CC; Das H
    Biochem Biophys Res Commun; 2005 Mar; 328(3):746-50. PubMed ID: 15694409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone metastases in prostate cancer: a targeted approach.
    Storey JA; Torti FM
    Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone directed therapies for prostate cancer.
    Bradley DA; Hussain M; Dipaola RS; Kantoff P
    J Urol; 2007 Sep; 178(3 Pt 2):S42-8. PubMed ID: 17644119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.